Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 24.9
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell